در هنگام جستجو کلمه در قسمت عنوان میتوانید کلمات مورد جستجو را با کاراکتر (-) جدا کنید.
کاربرد نوع شرط:
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Biomarker,MicroRNA,miR-155
- چکیده:
- چکیده انگلیسی: Background: Breast cancer incidence rates have been continuously increasing in majority nations with significant higher portion of cancer-related mortality in low- and middle-income countries. Developing new biomarker is an emerging field in the breast cancer research. Application of a promising minimally invasive biomarker, circulating microRNA, for additional improvement of diagnosis, prognosis, and therapeutic monitoring in breast cancer is not well corroborated. Materials and Methods: To uncover the potential use of circulating miR-155 expression as a clinical biomarker in breast cancer, we analyzed 102 breast cancer patients at diagnosis and after treatment as well as 15 healthy women. Total RNA was isolated from patient’s plasma and expression of circulating miR-155 was measured with quantitative reverse transcription polymerase chain reaction (qRT-PCR). The expression levels of circulating miR-155 were compared according to the effect of treatment, clinicopathological variables, and progression-free survival. Results: In comparison to the healthy women, expression of circulating miR-155 levels were significantly higher (medians were 18.49±19 and 1.28±0.18, respectively; p<0.0001). The expression levels of miR-155 were significantly diminished after patients completed surgery and chemotherapy (medians were 18.49±19 at diagnosis and 1.32±0.22 after treatment, respectively; p<0.0001). Patients older than 40 years old expressed higher circulating miR-155 than those younger than 40 years-old (medians were 28.92±22 and 4.19±2.49, respectively; p<0.0001). Circulating miR-155 was significantly higher in patients with tumors larger than 5 cm (44.27±2.6 vs 9.17±6.9, p=0.03). MiR-155 expression levels were not significantly different according to various tumor grades, subtypes, and clinical stages. Although longer follow-up is required, progression-free survivals of patients with upregulation of circulating miR-155 were significantly longer (mean survivals were 77 and 65 weeks, Log-rank (Mantel-Cox) test p=0.038). Conclusion: Expression of circulating miR-155 expression was significantly elevated in breast cancer patients and was decreased after treatment. Therefore, circulating miR-155 is potentially applicable as diagnostic therapeutic monitoring marker in breast cancer.
- انتشار مقاله: 09-07-1398
- نویسندگان: Sumadi Lukman Anwar,Dewi Sahfitri Tanjung,Meutia Srikandi Fitria,Aprilia Indra Kartika,Dwi Nur Indah Sari,Dinna Rakhmina,Tirta Wardana,Indwiani Astuti,Sofia Mubarika Haryana,Teguh Aryandono
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Biomarker,MicroRNA,miR-21,circulating
- چکیده:
- چکیده انگلیسی: Background: Aberrant patterns of microRNA expression have been highlighted as a potential clinical biomarker in
breast cancer as the most frequent cancer among women that contributes nearly a quarter of total cancer incidence in
2018. Upregulation of microRNA-21 (miR-21) is associated with adverse clinical outcomes in breast cancer. However,
the use of circulating free miR-21 as a non-invasive biomarker for diagnosis and therapeutic monitoring in breast
cancer is not well established. We quantified the levels of circulating miR-21 expression and analyzed their correlation
with clinicopathological variables and progression-free survival. Materials and Methods: This initial study included
a cohort of 102 breast cancer patients of different subtypes and clinicat stages. We also included 15 unrelated healthy
women. Venous blood from patients was collected at diagnosis and after treatment of surgery and chemotherapy.
MiR-21 expression was quantified from total RNA fraction isolated from patient’s plasma. Quantitative reverse
transcription polymerase chain reaction (qRT-PCR) was used to analyzed miR-21 expression. Results: Expression of
circulating miR-21 was significantly elevated in breast cancer patients compared to healthy women (median miR-21
expression levels were 7.67±2.2 and 1.28±0.16, respectively; p<0.0001). Significant reduction of miR-21 expression was
observed in breast cancer patients after completion of surgery and chemotherapy (median miR-21 expression levels were
7.67±2.2 at diagnosis and 2.16±1.28 after treatment, respectively; p<0.0001). MiR-21 expression was higher in breast
cancer patients younger than 40-year-old but was not significantly different according to different histopathological
grades and clinical stages at diagnosis. Patients with upregulation of circulating miR-21 were associated with poor
progression-free survival (median survival 72 vs 86 weeks, respectively; log-rank (Mantel-Cox) test, p=0.049).
Conclusion: MiR-21 expression was upregulated in breast cancer patients and might serve as a therapeutic monitoring
marker.- انتشار مقاله: 06-09-1397
- نویسندگان: Sumadi Lukman Anwar,Dwi Nur Indah Sari,Aprilia Indra Kartika,Meutia Srikandi Fitria,Dewi Sahfitri Tanjung,Dinna Rakhmina,Tirta Wardana,Indwiani Astuti,Sofia Mubarika Haryana,Teguh Aryandono
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Breast cancer,Survival,VEGF,Ki-67,Omega-3
- چکیده:
- چکیده انگلیسی: Background: Omega-3 is a polyunsaturated fatty acid with an ability to regulate cell proliferation and apoptosis
through interaction with inflammatory mediators. The potential additional beneficial effects of Omega-3 on chemotherapy
patients with breast cancer is not yet completely revealed. Methods: A double-blind randomized control trial (RCT)
involving a total of 48 locally advanced breast cancer patients was conducted. Ki-67 and VEGF expressions, as well as
overall survival of patients receiving neoadjuvant cyclophosphamide-doxorubicin-5’fluorouracyl (CAF) chemotherapy
plus Omega-3 (intervention group) or placebo (control group), were compared. Kaplan-Meier curve and Cox-regression
tests were used to assess conditional disease-free survival (DFS) and overall survival (OS) between the two groups.
Results: Decreased Ki-67 expression was observed in the intervention group compared to control (42.4±4.8 versus
39.2±5.3; T-test p=0.032). Decreased Ki-67 expression was observed in intervention compared to control group (42.4±4.8
versus 39.2±5.3; T-test p=0.032). Decreased VEGF expression was also seen in the intervention group compared to
control (32.7±5.2 versus 29.5±5.4; T-test p=0.041). VEGF expression positively correlated with Ki-67 expression
(Spearman’s test p<0.001, R2=0.541). Overall survival in the intervention group was significantly longer in comparison
to the control group (mean survival: 30.9 ± 3.71 versus 25.9 ± 3.6 weeks, Mantel-Cox test p=0.048; HR=0.411, 95%CI:
0.201-0.840). Disease-free survival was significantly longer in the intervention group compared to the control group
(mean survival: 28.5 ± 3.3 versus 23.7 ± 3.6, respectively; Mantel-Cox test p=0.044, HR= 0.439, 95%CI: 0.222-0.869).
Conclusion: Omega-3 fatty acid supplementation improved overall survival and progression-free survival of locally
advanced breast cancer treated with CAF neoadjuvant chemotherapy and mastectomy.- انتشار مقاله: 05-08-1397
- نویسندگان: Darwito Darwito,Edi Dharmana,Ignatius Riwanto,Selamat Budijitno,Suwardjo Suwardjo,Joko Purnomo,Irianiwati Widodo,Ahmad Ghozali,Teguh Aryandono,Sumadi Lukman Anwar
- مشاهده
- جایگاه : پژوهشی
- مجله: Asian Pacific Journal of Cancer Prevention
- نوع مقاله: Journal Article
- کلمات کلیدی: Survival,Breast carcinoma,Luminal and non-luminal subtype,lymphangiogenesis,VEGF-C
- چکیده:
- چکیده انگلیسی: Background: Breast carcinomas (BCs) are sub-classified according to the molecular characteristics into luminal and
non-luminal subtypes that clinically show different biological behavior, treatment and prognosis. BCs spread primarily
through lymphatic vessels using cascade processes of lymphagiogenesis in which VEGF-C plays an important role during
lymph node metastasis. Prognostic value of VEGF-C in luminal and non-luminal BC is still unclear and has not been
studied thoroughly to clarify and define prognosis and therapeutic monitoring. Aim: To define the prognostic value of
lymphangiogenesis on survival rates of luminal and non-luminal subtypes BC. Materials and Methods: This study
applied prospective cohort design, using 130 patients of invasive duct carcinoma of the breast, stage I-IIIA, from
Sardjito General Hospital, Indonesia and subsequent longitudinal follow-up. Immunohistochemical staining was
carried out using anti-ER, -PR, -Her-2, VEGF-C, VEGFR-3 and D2-40 antibodies. The related clinicopathologic
characteristics of BC patients and lymphangiogenesis determinants, including VEGF-C expression, were statistically
analyzed. Results: In non-luminal BC subtypes, VEGF-C expression (HR=0.04; 95% CI=0.01-0.41), lymph node
metastasis (HR=0.14; 95% CI=0.04-0.55) and stage (HR=0.30; 95% CI= 0.02-0.76) were determined as independent
prognostic factors on survival rates. However, the lymphangiogenesis determinants were not associated with the survival
rates of luminal BC subtypes. Conclusion: This study suggested that lymphangiogenesis affects survival rates of
non-Luminal subtype rather than the luminal subtypes of BC.- انتشار مقاله: 12-06-1396
- نویسندگان: Irianiwati Widodo,Ery Kus Dwianingsih,Totok Utoro,Sumadi Lukman Anwar,Teguh Aryandono,Soeripto .
- مشاهده